INHIBRX BIOSCIENCES INC (INBX)
Health Care · Clinical-stage immuno-oncology biopharmaceuticals · NASDAQ
Clinical-stage biotech leveraging proprietary protein engineering to develop novel multivalent death receptor and co-stimulatory agonists for oncology.
What INHIBRX BIOSCIENCES INC does
Inhibrx is a clinical-stage biopharmaceutical company developing novel biologic therapeutics using proprietary modular protein engineering platforms. The company was separated from Inhibrx, Inc. in May 2024 following a spin-off and Sanofi acquisition of the INBRX-101 program, and now focuses on two lead oncology programs: ozekibart (INBRX-109), a tetravalent DR5 agonist, and INBRX-106, a hexavalent OX40 agonist, both in clinical development for solid tumors.
Themes: ["oncology / cancer immunotherapy","death receptor agonists (DR5)","co-stimulatory agonists (OX40)","protein engineering / synthetic biology","clinical-stage biopharmaceuticals"]
Fundamentals
- Price$103.85 as of 2026-07-09 close
- Market cap$1.4B as of 2026-07-10
- 1-year return+387.0% as of 2026-07-09 close
- Net margin-5465.6% as of 2026-07-10
- ROE-256.0% as of 2026-07-10
- Debt / equity12.58 as of 2026-07-10
- Revenue growth (YoY)+550.0% as of 2026-07-10
- Revenue CAGR (3y)-15.0% SEC XBRL
- Beta2.92 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: both lead programs (ozekibart and INBRX-106) are in Phase 1-2 development with significant regulatory and efficacy hurdles ahead before any product approval or commercialization","Financial sustainability: company is pre-revenue and unprofitable with accumulated deficit of $279.6M as of Q1 2026, dependent on continued access to capital markets for financing operations and clinical development","Competition and intellectual property: entering crowded immuno-oncology market with established competitors and risk of patent invalidity or infringement claims against proprietary protein engineering platforms"]
Competitors & peers
- Genentech / Roche
- Merck
- Pfizer
- Gilead Sciences
- Novartis
- Jounce Therapeutics
- Arcus Biosciences
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.